Weekly low-dose docetaxel combined with estramustine and dexamethasone for Japanese patients with metastatic castration-resistant prostate cancer
International Journal of Clinical Oncology, 06/18/2012
Clinical Article
Hatano K et al. – The low–dose combination of docetaxel, estramustine and dexamethasone is active and tolerable with beneficial effects on serum prostate–specific antigen (PSA) levels, performance status, anemia and bone pain in Japanese patients with castration–resistant prostate cancer (CRPC). This regimen is a reasonable option for elderly patients with bone disease at risk of hematologic toxicity.
